Phase 1Not yet recruiting
A Phase 1, Open Label, non-randomised Drug-Drug interaction (DDI) for GV-100 (Part 4)
A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study of Single and Multiple Ascending Doses of GV-100 with Food-Effect and Drug-Drug Interaction Evaluations in Healthy Participants (Drug-Drug Interaction - Part4)
- Sponsor
- Gilva Therapeutics, INC.
- Enrolment
- 12 planned
- Conditions
- Autosomal Dominant Polycystic Kidney Disease (ADPKD); Renal and Urogenital - Kidney disease
- Ages
- adults, older adults
- Registry
- ACTRN12626001074381
Full record on ANZCTRSource: WHO ICTRP, processed 7 September 2026
Primary outcomes
- Safety and tolerability will be assessed comparatively as a composite outcome.[presence of Adverse Event's (AE), vital signs (blood pressure and heart rate measured using Blood pressure Machine, respiratory rate measured Manually, and body temperature measured using standard Thermometer), 12-lead El
History
Expected to start
Last registry update
Registered